NYSE:RLMDRelmada Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $36.29 -1.10 (-2.94 %) (As of 08/5/2020 12:48 PM ET) Add Compare Share Today's Range$35.90Now: $36.29▼$37.5150-Day Range$36.37MA: $43.00▼$49.9852-Week Range$8.08Now: $36.29▼$54.00Volume2,543 shsAverage Volume161,538 shsMarket Capitalization$551.54 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsHeadlinesOptions ChainSocial Media Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, and proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Relmada Therapeutics. Previous Next 2.7 Community Rank Outperform VotesRelmada Therapeutics has received 6 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRelmada Therapeutics has received 5 “underperform” votes. (Add your “underperform” vote.)Community SentimentRelmada Therapeutics has received 54.55% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Relmada Therapeutics and other stocks. Vote “Outperform” if you believe RLMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RLMD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRelmada Therapeutics does not currently pay a dividend.Dividend GrowthRelmada Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Relmada Therapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.54 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Drug Manufacturers—Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolNYSE:RLMD Previous Symbol CUSIPN/A CIKN/A Webwww.relmada.com Phone646-876-3459Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees4 Outstanding Shares15,198,000Market Cap$551.54 million Next Earnings Date9/22/2020 (Estimated) OptionableOptionable $36.29 -1.10 (-2.94 %) (As of 08/5/2020 12:48 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive RLMD News and Ratings via Email Sign-up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Relmada Therapeutics (NYSE:RLMD) Frequently Asked Questions How has Relmada Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Relmada Therapeutics' stock was trading at $40.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RLMD stock has decreased by 9.7% and is now trading at $36.29. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Relmada Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Relmada Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Relmada Therapeutics. When is Relmada Therapeutics' next earnings date? Relmada Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, September 22nd 2020. View our earnings forecast for Relmada Therapeutics. How were Relmada Therapeutics' earnings last quarter? Relmada Therapeutics, Inc. (NYSE:RLMD) released its quarterly earnings results on Friday, May, 15th. The company reported ($0.72) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.39. View Relmada Therapeutics' earnings history. Has Relmada Therapeutics been receiving favorable news coverage? Media coverage about RLMD stock has been trending somewhat negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Relmada Therapeutics earned a news impact score of -1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near future. View the latest news about Relmada Therapeutics. Who are some of Relmada Therapeutics' key competitors? Some companies that are related to Relmada Therapeutics include Canopy Rivers (RIV), Medipharm Labs (LABS), Khiron Life Sciences (KHRN), Willow Biosciences (WLLW), National Access Cannabis (META), 48North Cannabis (NRTH), Cronos Australia (CAU), Two Rivers Water & Farming (MJNE), Kali (RDGL), 4Front Ventures (PCLOF), AAC Technologies (ABSCF), Abattis Bioceuticals (ATT), Aft Pharmaceuticals (AFP), AgraFlora Organics International (AGRA) and AgraFlora Organics International (AGFAF). View all competitors. What other stocks do shareholders of Relmada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Relmada Therapeutics investors own include Advanced Micro Devices (AMD), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), NVIDIA (NVDA), AbbVie (ABBV), Alteryx (AYX), Crispr Therapeutics (CRSP), Medtronic (MDT) and Micron Technology (MU). Who are Relmada Therapeutics' key executives? Relmada Therapeutics' management team includes the following people: Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA, CEO & Director (Age 60)Dr. Ottavio V. Vitolo M.D., Sr. VP, Head of R&D and Chief Medical Officer (Age 48)Mr. Charles S. Ence, Chief Financial Officer (Age 55)Ms. Gina DiGuglielmo, VP & Head of Clinical OperationsDr. Richard M. Mangano, Consultant (Age 70) What is Relmada Therapeutics' stock symbol? Relmada Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "RLMD." How do I buy shares of Relmada Therapeutics? Shares of RLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Relmada Therapeutics' stock price today? One share of RLMD stock can currently be purchased for approximately $36.29. How big of a company is Relmada Therapeutics? Relmada Therapeutics has a market capitalization of $551.54 million. Relmada Therapeutics employs 4 workers across the globe. What is Relmada Therapeutics' official website? The official website for Relmada Therapeutics is www.relmada.com. How can I contact Relmada Therapeutics? The company can be reached via phone at 646-876-3459. This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
